Companies › OPKO Health
2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 2; Other, Metabolic and endocrine; next expected readout Oct 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Calcifediol (CTAP101) Vitamin D receptor agonist | VDR | Phase 2 | CKD Stage 3 | Oct 2027 |
| OPK-88006 unclear - MASH therapeutic, mechanism not specified in registry | – | Phase 1 | MASH | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07494045 | Calcifediol (CTAP101) | Phase 2 | CKD Stage 3 | Metabolic and endocrine | Oct 2027 |
| NCT07512427 | OPK-88006 | Phase 1 | MASH | Other | Dec 2027 |
Cash of $384m on 2026-09-30; operating cash outflow about $133m a year; runway about 35 months at that burn, to Aug 2029; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) BrightGene Bio-Medical Technology Eloxx Pharmaceuticals Kylonova (Xiamen) Biopharma Energenesis Biomedical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.